You are currently viewing a new version of our website. To view the old version click .

Neurology International, Volume 14, Issue 2

June 2022 - 19 articles

Cover Story:

In MS patients, risk factors for severe evolution of COVID-19 are older age, male gender, an EDSS score of >3, comorbidities, methylprednisolone administered in the month before infection, anti-CD20 therapy, and progressive MS course. A reduced vaccine humoral response has been described in patients on ocrelizumab and fingolimod, and a low antibody titer has been associated with the risk of SARS-CoV-2 breakthrough infection.

We suggest evaluating single patient risk factors for COVID-19 severe evolution and anti-SARS-CoV-2 antibodies titer in order to better identify those MS persons at risk of developing severe COVID-19 and to discuss with them the opportunity to administer a prophylactic therapy (i.e., tixagevimag/cilgavimab) or to treat SARS-CoV-2 infection with antivirals and/or anti-spike protein monoclonal antibodies. View this paper

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (19)

  • Article
  • Open Access
38 Citations
4,935 Views
11 Pages

Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort

  • Antonino Lupica,
  • Vincenzo Di Stefano,
  • Salvatore Iacono,
  • Antonia Pignolo,
  • Martina Quartana,
  • Andrea Gagliardo,
  • Brigida Fierro and
  • Filippo Brighina

27 April 2022

Background and aims. Patients with Myasthenia gravis (MG) are considered vulnerable as they may present with respiratory muscle weakness and because they are on immunosuppressive treatment; thereby, COVID-19 may have a detrimental effect on these pat...

  • Review
  • Open Access
42 Citations
6,254 Views
15 Pages

Ischemic Stroke and SARS-CoV-2 Infection: The Bidirectional Pathology and Risk Morbidities

  • Vishal Chavda,
  • Bipin Chaurasia,
  • Alessandro Fiorindi,
  • Giuseppe E. Umana,
  • Bingwei Lu and
  • Nicola Montemurro

24 April 2022

Stroke is a fatal morbidity that needs emergency medical admission and immediate medical attention. COVID-19 ischemic brain damage is closely associated with common neurological symptoms, which are extremely difficult to treat medically, and risk fac...

  • Article
  • Open Access
3 Citations
3,352 Views
13 Pages

Volume of Amygdala Subregions and Plasma Levels of Brain-Derived Neurotrophic Factor and Cortisol in Patients with s/s Genotype of Serotonin Transporter Gene Polymorphism of First-Episode and Drug-Naive Major Depressive Disorder: An Exploratory Study

  • Naomichi Okamoto,
  • Keita Watanabe,
  • Hirofumi Tesen,
  • Atsuko Ikenouchi,
  • Ryohei Igata,
  • Yuki Konishi,
  • Tomoya Natsuyama,
  • Rintaro Fujii,
  • Shingo Kakeda and
  • Taro Kishi
  • + 2 authors

15 April 2022

The amygdala is a prominent region of the brain that plays a critical role in the pathophysiology of major depressive disorder (MDD). The amygdala is formed from a collection of interconnected substructures (nuclei) that relay signals from multiple b...

  • Review
  • Open Access
6 Citations
3,661 Views
10 Pages

Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach

  • Paolo Immovilli,
  • Nicola Morelli,
  • Chiara Terracciano,
  • Eugenia Rota,
  • Elena Marchesi,
  • Stefano Vollaro,
  • Paola De Mitri,
  • Domenica Zaino,
  • Veronica Bazzurri and
  • Donata Guidetti

15 April 2022

The COVID-19 pandemic poses an ongoing global challenge, and several risk factors make people with multiple sclerosis (pwMS) particularly susceptible to running a severe disease course. Although the literature does report numerous articles on the ris...

  • Article
  • Open Access
9 Citations
4,203 Views
11 Pages

Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer’s Disease

  • Chiara Fornari,
  • Francesco Mori,
  • Nicola Zoppi,
  • Ilenia Libri,
  • Chiara Silvestri,
  • Maura Cosseddu,
  • Rosanna Turrone,
  • Matteo Maffi,
  • Salvatore Caratozzolo and
  • Barbara Borroni
  • + 2 authors

6 April 2022

New diagnostic methods have been developed for the early diagnosis of Alzheimer’s disease (AD) with the primary purpose of intercepting the transition-phase (mild cognitive impairment, MCI) between normal aging and dementia. We aimed to explore...

  • Feature Paper
  • Review
  • Open Access
23 Citations
5,514 Views
20 Pages

Mitochondrial Ataxias: Molecular Classification and Clinical Heterogeneity

  • Piervito Lopriore,
  • Valentina Ricciarini,
  • Gabriele Siciliano,
  • Michelangelo Mancuso and
  • Vincenzo Montano

2 April 2022

Ataxia is increasingly being recognized as a cardinal manifestation in primary mitochondrial diseases (PMDs) in both paediatric and adult patients. It can be caused by disruption of cerebellar nuclei or fibres, its connection with the brainstem, or s...

  • Article
  • Open Access
7 Citations
3,143 Views
14 Pages

Cortical Oxygenation during a Motor Task to Evaluate Recovery in Subacute Stroke Patients: A Study with Near-Infrared Spectroscopy

  • Nicola Lamberti,
  • Fabio Manfredini,
  • Francesca Nardi,
  • Andrea Baroni,
  • Giovanni Piva,
  • Anna Crepaldi,
  • Nino Basaglia,
  • Ilaria Casetta and
  • Sofia Straudi

23 March 2022

In subacute stroke patients we studied cortical oxygenation changes by near-infrared spectroscopy (NIRS) during a motor task performed with the hemiparetic arm (15 s of reaching and grasping, 45 s of rest, repeated 6 times). Twenty-three subjects wer...

  • Review
  • Open Access
33 Citations
7,902 Views
12 Pages

The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease

  • Islam Mohammad Shehata,
  • Waniyah Masood,
  • Nouran Nemr,
  • Alexandra Anderson,
  • Kamal Bhusal,
  • Amber N. Edinoff,
  • Elyse M. Cornett,
  • Adam M. Kaye and
  • Alan D. Kaye

22 March 2022

Depression is a leading cause of disability globally, with a prevalence of 3.8% among the whole population, 5% of the adult population, and 5.7% of the elderly population over 60 years of age. There is evidence that depression is linked to certain ne...

of 2

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Neurol. Int. - ISSN 2035-8377